Free Trial

Russell Investments Group Ltd. Has $845,000 Holdings in Criteo S.A. (NASDAQ:CRTO)

Russell Investments Group Ltd. lowered its position in shares of Criteo S.A. (NASDAQ:CRTO - Free Report) by 62.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,375 shares of the information services provider's stock after selling 55,834 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.05% of Criteo worth $845,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new position in Criteo during the third quarter worth approximately $15,306,000. Jump Financial LLC acquired a new position in Criteo in the third quarter valued at $683,000. VELA Investment Management LLC grew its position in Criteo by 83.4% during the third quarter. VELA Investment Management LLC now owns 81,525 shares of the information services provider's stock valued at $2,381,000 after acquiring an additional 37,074 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Criteo during the third quarter valued at about $394,000. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Criteo by 20.0% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 160,674 shares of the information services provider's stock worth $4,692,000 after purchasing an additional 26,800 shares during the period. 94.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Criteo

In other news, CEO Megan Clarken sold 5,485 shares of Criteo stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $35.00, for a total value of $191,975.00. Following the completion of the transaction, the chief executive officer now owns 552,933 shares in the company, valued at approximately $19,352,655. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Megan Clarken sold 5,485 shares of Criteo stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $35.00, for a total value of $191,975.00. Following the completion of the transaction, the chief executive officer now directly owns 552,933 shares of the company's stock, valued at approximately $19,352,655. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Sarah Js Glickman sold 9,653 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $32.69, for a total transaction of $315,556.57. Following the sale, the chief financial officer now owns 293,019 shares in the company, valued at approximately $9,578,791.11. The disclosure for this sale can be found here. Insiders sold a total of 110,268 shares of company stock valued at $3,736,371 over the last three months. 1.71% of the stock is owned by insiders.


Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CRTO shares. KeyCorp boosted their target price on Criteo from $36.00 to $37.00 and gave the stock an "overweight" rating in a report on Wednesday, May 1st. Susquehanna increased their price objective on shares of Criteo from $33.00 to $40.00 and gave the stock a "neutral" rating in a research report on Monday, May 6th. Benchmark restated a "buy" rating and set a $40.00 target price on shares of Criteo in a report on Tuesday, April 30th. StockNews.com upgraded Criteo from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 8th. Finally, TheStreet upgraded Criteo from a "c" rating to a "b-" rating in a research note on Friday, February 9th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $37.89.

Read Our Latest Stock Report on Criteo

Criteo Price Performance

CRTO traded up $0.74 during trading on Monday, hitting $37.24. The company had a trading volume of 309,114 shares, compared to its average volume of 264,599. Criteo S.A. has a 1-year low of $22.10 and a 1-year high of $39.54. The company has a market cap of $2.11 billion, a PE ratio of 38.39 and a beta of 0.95. The business has a 50-day moving average of $35.72 and a 200-day moving average of $29.88.

Criteo Company Profile

(Free Report)

Criteo SA, a technology company, provides marketing and monetization services on the open Internet in North and South America, Europe, the Middle East, Africa, and the Asia-Pacific. The company's Criteo Shopper Graph, which derives clients' proprietary commerce data, such as transaction activity on their digital properties.

See Also

Institutional Ownership by Quarter for Criteo (NASDAQ:CRTO)

Should you invest $1,000 in Criteo right now?

Before you consider Criteo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Criteo wasn't on the list.

While Criteo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Featured Articles and Offers

Biotech Boom: Stocks Skyrocketing & What's Next

Biotech Boom: Stocks Skyrocketing & What's Next

Dive into biotech's latest trends with Dylan Jovine: weight loss breakthroughs, smart chemo innovations, and expert stock evaluation tips.

Search Headlines: